Individual patient data analysis of the BIOFLOW study program comparing safety and efficacy of a bioresorbable polymer sirolimus eluting stent to a durable polymer everolimus eluting stent

Ralph Toelg MD\textsuperscript{1} | Ton Slagboom MD\textsuperscript{2} | Johannes Waltenberger MD\textsuperscript{3} \textsuperscript{₃} | Thierry Lefèvre MD\textsuperscript{4} | Shigeru Saito MD\textsuperscript{5} \textsuperscript{₅} | David E. Kandzari MD\textsuperscript{6} \textsuperscript{₆} | Jacques Koolen MD\textsuperscript{7} | Gert Richardt MD\textsuperscript{1} \\
\textsuperscript{1}Herzzentrum, Segeberger Kliniken GmbH, Bad Segeberg, Germany \\
\textsuperscript{2}Heartcenter, OLVG, Amsterdam, The Netherlands \\
\textsuperscript{3}Klinik für Innere Med. I, SRH Zentralklinikum Suhl gGmbH, Suhl, Germany \\
\textsuperscript{4}Hospital Privé Jacques Cartier, Massy, France \\
\textsuperscript{5}Department of Cardiology, Okinawa Tokushukai Shonan Kamakura General Hospital, Kamakura, Japan \\
\textsuperscript{6}Piedmont Heart Institute, Atlanta, Georgia \\
\textsuperscript{7}Catharina Hospital, Eindhoven, The Netherlands

Abstract

Objectives: This analysis of pooled individual patient data (IPD) aimed to evaluate the safety and efficacy of a bioresorbable polymer sirolimus eluting stent system (BP-SES; Orsiro) compared to a durable polymer everolimus eluting stent system (DP-EES; Xience) in the pooled population as well as in subgroups.

Methods: IPD with up to 12 months follow-up of the randomized controlled trials BIOFLOW-II (NCT01356888), -IV (NCT01939249), and -V (NCT02389946) as well as the all comers registry BIOFLOW-III (NCT01553526) were pooled. A total of 3,717 subjects (2,923 in BP-SES and 794 in DP-EES) with 5,328 lesions (4,225 lesions in BP-SES and 1,103 in DP-EES) were included in the IPD. The primary endpoint was target lesion failure (TLF) at 12 months follow-up. Subgroups analyzed included diabetes, age ($\geq 65$ years), gender, complex lesions (B2/C), small vessels (reference vessel diameter $\leq 2.75$ mm), multivessel treatment, renal disease, and patients with acute coronary syndrome.

Results: Overall, TLF at 12 months was significantly lower with 5.2% in the BP-SES group versus 7.6% in the DP-EES group ($p = .0098$). Similarly, target vessel myocardial
Contemporary drug eluting stents (DES) with metallic backbones are characterized by a distinguished safety and efficacy profile compared to previous generations and are therefore the default devices in patients undergoing percutaneous coronary intervention (PCI). The bioresorbable sirolimus eluting stent (BP-SES, Orsiro, BIOTRONIK AG) is a DES, which is known for its ultrathin struts made of cobalt-chromium. The strut thickness is 60 μm for stent sizes up to 3.0 mm and 80 μm for sizes >3.0 mm in expanded diameter. BP-SES is further characterized by a unique hybrid coating consisting of a bioresorbable drug-polymer combination, which ultimately only leaves the bare metal stent in the vessel covered by a passive coating layer of amorphous silicon carbide. The high clinical safety and efficacy profile of BP-SES has been demonstrated in several randomized controlled trials (RCTs) with either de novo lesions or in all comers populations, corroborated by results seen in all comers registries and the SCAAR registry. The BP-SES has been repeatedly compared to other DES (e.g., the durable polymer everolimus eluting stent [DP-EES], Xience, Abbott, the durable polymer zotarolimus eluting stent [DP-ZES] Resolute Onyx and Resolute Integrity, Medtronic) demonstrating comparable results and safety profiles. In the BIOFLOW-V trial, a RCT in an almost all-comers population, a significant reduction in both the target lesion failure (TLF) rate and target vessel myocardial infarction rate (TV-MI) was observed for the BP-SES group compared to DP-EES. Meanwhile, several meta-analyses were conducted comparing the clinical outcomes of BP-SES with contemporary DES. In a meta-analysis by Cassese et al. including six RCTs comparing BP-SES against DP-EES, clinical outcomes were comparable between the groups at 12 months follow-up. Similarly, Lipinski et al. assessed the data of eight RCTs comparing BP-SES against various DES. They showed a trend toward reduction of MI, TLF, and stent thrombosis (ST) for patients treated with BP-SES. Zhu et al. considered six RCTs comparing BP-SES with two different durable polymer stents for the meta-analysis, in which a significantly reduced risk for MI in BP-SES treated subjects was found. As the majority of these analyses were performed at publication level, detailed analyses of different patient subgroups were not possible. Hence, this pooled individual patient data (IPD) analysis of the BIOFLOW-II, BIOFLOW-III, BIOFLOW-IV, and BIOFLOW-V studies aimed to evaluate the safety and efficacy of BP-SES compared to DP-EES in the overall pooled population as well as in certain patient subgroups.

Materials and Methods

2.1 Individual patient data analysis: studies included

BIOFLOW-II was a 2:1 RCT with 452 patients comparing BP-SES with a DP-EES (Xience Prime). The primary endpoint was in-stent late lumen loss (LLL): 0.10 ± 0.32 mm in BP-SES versus 0.11 ± 0.29 mm in DP-EES, p non-inferiority < .0001 at 9 months. TLF at 12 months was 6.5% in BP-SES versus 8.0% in DP-EES.

BIOFLOW-III was a prospective, multicenter observational all-comers registry with 1,356 patients enrolled. The primary endpoint was TLF at 12 months was 5.1% in the overall population.

BIOFLOW-IV was a 2:1 RCT with 525 patients comparing BP-SES with DP-EES (Xience Prime or Xience Xpedition). The primary endpoint non-inferiority related to 12-months target vessel failure (TVF), was met (5.1% in BP-SES patients versus 6.6% in DP-EES patients, p non-inferiority < .001). TLF at 12 months was 4.2% in BP-SES versus 5.4% in DP-EES.

BIOFLOW-V was a 2:1 RCT with 1,334 patients comparing BP-SES with DP-EES. TLF at 12 months rate was 6% in BP-SES versus 10% in DP-EES (p = .0399).

In all trials, the endpoint related events used for this analysis were adjudicated by an independent clinical event committee. This IPD analysis was investigator initiated using the trial data on file hold on property by BIOTRONIK AG, Buelach, Switzerland. The principal investigators of the primary main trials agreed on conducting this analysis. All authors had full access to the data of this analysis and had final responsibility for the decision to submit for publication (Table S1).

2.2 Endpoint and subgroups

The primary endpoint of this retrospective IPD analysis was TLF at 12 months in the overall population. Secondary endpoints were TLF and TV-MI.
at 12 months in pre-defined subgroups such as diabetes, gender, age ≥ 65 years, multivessel treatment, B2/C complex lesions, small vessels ≤2.75 mm in diameter, nominal stent size ≤3.0 mm diameter, renal disease, as well as subjects presenting with acute coronary syndrome (ACS). Additional secondary endpoints were the individual components of TLF: TV-MI, clinically driven target lesion revascularization (TLR), and cardiac death (CD) at 12 months in the overall population and in the pre-defined subgroups.

2.3 | Statistical methods

The IPD analysis from the four studies was performed according to the intention-to-treat (ITT) principle including all randomized patients. Only complete cases were included with no imputation of missing data. SAS v9.4 was used for analysis.

Categorical baseline variables were summarized as absolute and relative frequencies and compared between the two device groups using Chi-square tests. Continuous baseline variables were listed as means and SDs and compared using the non-parametric Wilcoxon sum-rank test. The aim of the analysis was to estimate the device effect on the binary 1-year TLF rate, applying the Universal MI definition.

Stratified subgroup analyses included diabetes, age (≥65 years), gender, complex lesions (B2/C), small vessels (reference vessel diameter [RVD] ≤ 2.75 mm), nominal stent size ≤3.0 mm diameter, multivessel treatment, renal disease, and patients with ACS. In order to correct for potential confounding, multivariate mixed effect logistic regression was developed, using the TLF rate at 12 months as the dependent variable and the following independent variables: Device, study (random effect), diabetes, age (≥ 65 years), gender, hypertension, smoking status, renal disease, cancer, complex lesion, multivessel treatment, small vessel ≤2.75 mm in diameter, pre-dilatation, post-dilatation, and ACS status. As BP-SES stent sizes vary in strut thickness, the regression analysis was repeated for patients treated with stents ≤3.0 mm diameter with only 60 µm strut thickness. An initial model was fitted including interaction terms of every fixed effect with the device. Type III effects p-values were used to determine the significance.

As a significant interaction between small vessel ≤2.75 mm in diameter and the device was observed (p = .0109), two final models were fitted separately without interactions—for small and large vessels. The estimates for individual effect were presented as odds ratios (OR) with 95% confidence intervals (CI) and presented graphically with forest plots.

3 | RESULTS

The overall data of 3,717 subjects (2,923 in BP-SES and 794 in DP-EES) with 5,328 lesions (4,225 lesions in BP-SES and 1,103 in DP-EES) were included in this IPD. The main characteristics of the patients are reported in Table 1. The mean age was 65.5 ± 10.5 years, 73.5% were male. The main risk factors at baseline were hypertension (77.4%), hypercholesterolemia (69.4%), past or present smoking history (58.5%), and 31.5% diabetes mellitus. Previous MI was observed in 28.2% of cases. There were significantly less patients presenting with hypercholesterolemia in BP-SES than in DP-EES (67.7 vs. 78.2%, p < .0001) and more patients with renal disease (9.7 vs. 7.2%, p < .05). With respect to ischemic status at baseline, more patients in the BP-SES group presented with stable angina while unstable angina was more frequent for DP-EES subjects (60.4 vs. 52.2% and 25.6 vs. 30.9%, respectively, p = .0002). Additionally, more patients suffered from ACS (unstable angina, acute myocardial infarction) for the BP-SES group (36.8% for BP-SES vs. 30.9% DP-SES, p = .0020). The lesion characteristics differed between the groups as more patients presented with complex B2/C lesions in the DP-EES group (53.7% for BP-SES and 57.6% for DP-EES, p = .0296, Table 2). On the contrary, more patients in the BP-SES group showed a thrombus at baseline (5.4 vs. 0.8%, p < .0001). In the overall group, the mean RVD was 2.75 ± 0.52 mm and lesion lengths 14.3 ± 8.01 mm. Diameter stenosis (DS) pre-procedure was higher in the BP-SES group (73.0 ± 18.3% vs. 60.2 ± 14.6%, p < .0001). There were some significant differences with respect to procedural details, like slightly and physically irrelevant higher implantation pressure in BP-SES, but a higher rate of pre- and post-dilatation in DP-EES (Table 2). Altogether this resulted in a slightly but formally significant difference in post-procedural DS (7.3 ± 11.7% in BP-SES vs. 7.5 ± 8.5% in DP-EES, p < .0001). However, those minimal differences in lesion length and DS judged by the visual estimation of the investigators have to be taken carefully.

Overall TLF rate at 12 months (Figure 1) was lower in the BP-SES group; 5.2 vs. 7.6% (OR = 0.67, 95% CI [0.49; 0.91]; p = .0098). This difference was driven (Figure 2) by a significantly lower rate of TV-MI: 3.1 versus 5.7% (OR = 0.53 with 95% CI [0.37; 0.76]; p = .0005). The other composites of TLF (CD and clinically driven TLR) were similar (Figure S1 and Figure S2). The rate of definite or probable ST was also similar (3.1 versus 5.7% (OR = 0.53 with 95% CI [0.37; 0.76]; p = .0005). The other composites of TLF (CD and clinically driven TLR) were similar (Figure S1 and Figure S2). The rate of definite or probable ST was also similar (3.1 versus 5.7% (OR = 0.53 with 95% CI [0.37; 0.76]; p = .0005). The other composites of TLF (CD and clinically driven TLR) were similar (Figure S1 and Figure S2). The rate of definite or probable ST was also similar (3.1 versus 5.7% (OR = 0.53 with 95% CI [0.37; 0.76]; p = .0005). The other composites of TLF (CD and clinically driven TLR) were similar (Figure S1 and Figure S2). The rate of definite or probable ST was also similar (3.1 versus 5.7% (OR = 0.53 with 95% CI [0.37; 0.76]; p = .0005). The other composites of TLF (CD and clinically driven TLR) were similar (Figure S1 and Figure S2). The rate of definite or probable ST was also similar (3.1 versus 5.7% (OR = 0.53 with 95% CI [0.37; 0.76]; p = .0005). The other composites of TLF (CD and clinically driven TLR) were similar (Figure S1 and Figure S2). The rate of definite or probable ST was also similar (3.1 versus 5.7% (OR = 0.53 with 95% CI [0.37; 0.76]; p = .0005). The other composites of TLF (CD and clinically driven TLR) were similar (Figure S1 and Figure S2). The rate of definite or probable ST was also similar (3.1 versus 5.7% (OR = 0.53 with 95% CI [0.37; 0.76]; p = .0005). The other composites of TLF (CD and clinically driven TLR) were similar (Figure S1 and Figure S2). The rate of definite or probable ST was also similar (3.1 versus 5.7% (OR = 0.53 with 95% CI [0.37; 0.76]; p = .0005). The other composites of TLF (CD and clinically driven TLR) were similar (Figure S1 and Figure S2). The rate of definite or probable ST was also similar (3.1 versus 5.7% (OR = 0.53 with 95% CI [0.37; 0.76]; p = .0005).
had a dominant effect on the results observed which could be excluded.

In order to identify potential predictors for TLF, we performed a regression analysis. Multivessel treatment ($p = .0364$), post-dilatation ($p < .001$), RVD $\leq 2.75$ mm ($p = .0075$), and stent diameter $\leq 3.0$ mm ($p = .0521$) were identified as predictors of TLF rates at 12 months. In addition, we observed an interaction between both RVD $\leq 2.75$ mm and stent type implanted ($p = .0109$) as well as stent

### TABLE 1  Clinical characteristics at baseline

|                      | BP-SES $N = 2,923$ patients | DP-EES $N = 794$ patients | Overall $N = 3,717$ patients | $p$-value |
|----------------------|-----------------------------|---------------------------|-------------------------------|-----------|
| Mean age years ± SD  | 65.1 ± 10.5                 | 64.6 ± 10.2               | 65.5 ± 10.5                   |           |
| Age ≥ 65 years (%)   | 1,602 (54.8)                | 412 (51.9)                | 2014 (54.2)                   | .1434     |
| Male (%)             | 73.3 (2,144/2923)           | 74.2 (589/794)            | 73.5 (2,733/3717)             | .64       |
| Female (%)           | 26.7 (779/2923)             | 25.8 (205/794)            | 26.5 (984/3717)               | .6375     |
| Hypertension %       | 77.4 (2,252/2910)           | 77.7 (609/784)            | 77.4 (2,861/3694)             | .86       |
| Hypercholesterolemia | 67.7% (1,973/2917)          | 78.2% (786/979)           | 69.9% (2,592/3710)            | <.0001    |
| Smoking history      | 58.2% (1,701/2922)          | 59.6% (473/794)           | 58.5% (2,174/3716)            | .49       |
| History of previous MI | 28.2% (818/2905)     | 26.4% (208/788)           | 27.8% (1,026/3693)            | .33       |
| Diabetes mellitus    | 30.9% (902/2921)           | 33.8% (268/793)           | 31.5% (1,170/3714)            | .12       |
| History of stroke or TIA | 6.1% (179/2920)   | 6.2% (49/792)             | 6.1% (228/3712)               | .95       |
| Renal disease %      | 9.7% (283/2920)            | 7.2% (57/794)             | 9.2% (340/3715)               | <.05      |
| Cancer %             | 8.5% (249/2919)            | 10.2% (81/794)            | 8.9% (330/3713)               | .14       |
| Ischemic status at baseline |                   |                           |                               | .0002     |
| Stable angina        | 60.4% (1,497/2477)         | 52.2% (414/793)           | 58.4% (1,911/3270)            |           |
| Documented silent ischemia | 14.0% (347/2477)     | 16.9% (134/793)           | 14.7% (481/3270)              | .3816     |
| Unstable angina      | 25.6% (633/2477)           | 30.9% (245/793)           | 26.9% (878/3270)              |           |
| Acute coronary syndrome & | 36.8% (1,075/2919) | 30.9% (245/793)           | 35.6% (1,320/3712)            | .0020     |

Abbreviations: BP-SES, bioresorbable polymer sirolimus eluting stent; DP-EES, permanent polymer everolimus eluting stent; MI, myocardial infarction; TIA, transient ischemic attack.

### TABLE 2  Lesion characteristics and procedural parameters

|                      | BP-SES $N = 4,225$ lesions | DP-EES $N = 1,103$ lesions | Overall $N = 5,328$ lesions | $p$-value |
|----------------------|-----------------------------|---------------------------|-------------------------------|-----------|
| Multivessel treatment| 10.8 (315/2912)             | 12.6 (99/786)             | 11.2 (414/3698)               | .1606     |
| Lesion               |                             |                           |                               |           |
| Complex lesion (B2/C)| 53.7% (1,906/3548)          | 57.6% (544/943)           | 54.5% (2,450/4491)            | .0296     |
| Severe calcification | 5.3% (190/3554)             | 4.6% (44/949)             | 4.3% (88/2,000)               | .3816     |
| Bifurcation          | 13.6% (485/3564)            | 11.3% (107/949)           | 11.8% (204/2,013)             | .0585     |
| Thorbosis            | 5.4% (189/3524)             | 0.8% (8/949)              | 4.4% (179/4,473)              | <.0001    |
| Lesion length mm (mean ± SD) | 18.7 ± 6.3 (14.3; 14.8) | 19.2 ± 7.1 (12.9;13.8) | 14.3 ± 8.0 (14.05; 14.52) | <.0001    |
| Reference vessel diameter (mean ± SD and (95% CI) | 2.78 ± 0.51 (2.76;2.80) | 2.64 ± 0.55 (2.60; 2.68) | 2.75 ± 0.52 (2.74; 2.77) | <.0001    |
| Maximum implantation pressure | 14.0 ± 3.0 | 13.8 ± 2.8 | 14.0 ± 3.0 | <.01     |
| Stent length mm (mean ± SD) | 18.8 ± 6.5 | 18.7 ± 6.3 | 19.2 ± 7.1 | .34       |
| Diameter stenosis pre-procedure (mean ± SD and (95% CI) | 73.0 ± 18.3 (72.4;73.6) | 60.2 ± 14.6 (59.3; 61.1) | 70.3 ± 18.3 (69.7; 70.8) | <.0001    |
| Diameter stenosis post-procedure (mean ± SD and (95% CI) | 7.3 ± 11.7 (6.8;7.8) | 7.5 ± 8.5 (7.0;8.1) | 7.4 ± 10.8 (7.0; 7.8) | .0024     |
| Pre-dilatation       | 76.7 (2,789/3635)           | 86.2 (846/981)            | 87.3 (3,635/4616)             | <.0001    |
| Post-dilatation      | 34.2 (1,243/3634)           | 42.4 (416/981)            | 35.9 (1,659/4615)             | <.0001    |

Abbreviations: ACS, acute coronary syndrome, BP-SES, bioresorbable polymer sirolimus eluting stent; DP-EES, permanent polymer everolimus eluting stent; TIA, transient ischemic attack.

Toelg et al.
diameter ≤ 3.0 mm and stent type used (p = .0351) in favor of BP-SES. On the contrary, no interactions with the type of treatment were found for post-dilatation or multivessel treatment suggesting that those factors influence the clinical outcome independent of the implanted study stent.

In a second step, the model was tested in subjects with RVD ≤ 2.75 mm only to confirm the positive treatment effect of BP-SES in this subgroup; the treatment effect was in favor of the BP-SES stent for TLF (OR 0.51; 95% CI [0.33; 0.81], p = .0039, Figure 3) as well as TV-MI (OR 0.58; 95% CI [0.35; 0.97], p = .0377, Figure 4) at 12 months. On the contrary, in patients with RVD > 2.75 mm no treatment effect of the stent type used was detected on either TLF or TV-MI (Figures S3 and S4). As patients with at least one small lesion were predominantly treated with stents up to 3.0 mm in diameter, the model was repeated in the subgroup of subjects treated with at least one stent with a diameter ≤ 3.0 mm. Interestingly, a similar effect in
favor of BP-SES was seen in those patients for TLF (OR = 0.51 with 95% CI [0.33; 0.79]; p = .0024, Figure S5) and TV-MI (OR = 0.55 with 95% CI [0.34; 0.90]; p = .0165, Figure S6).

4 | DISCUSSION

As the main finding of this pooled analysis, BP-SES proved to be better with respect to TLF, mainly driven by a significantly lower rate of TV-MI compared to DP-EES. The ST rate was very low without a difference between the two-stent groups. In a consecutive subgroup analysis, the use of the ultra-thin strut BP-SES in small vessels turned out of significant benefit. Patients with small target vessels of ≤2.75 mm in diameter are known to be at increased risk of TLF due to increased rates of restenosis and repeat revascularisation.20,21 On the contrary, several DES have been studied in patients with small target vessels with comparable clinical outcomes to those seen for larger vessel sizes.22-24 Further, subgroup analyses of previous studies with the BP-SES (BIOFLOW-II, BIOFLOW-III, and BIOSCIENCE, respectively) demonstrated that BP-SES is safe and effective in the
treatment of lesions in small vessels at a 12-month follow-up. A recent post hoc analysis of the BIOSCIENCE trial confirmed that both BP-SES and DP-EES are equally safe and effective for treatment of patients with small target vessels ≤3 mm up to 5 years follow-up. However, as DES with thinner struts have generally been associated with lower risk for restenosis especially in smaller target vessels, the BP-SES with its ultrathin 60 μm struts is expected to be a very good treatment option for coronary artery disease in small vessels.

In this IPD analysis we found in a regression analysis a positive treatment effect in favor of BP-SES for TLF and TV-MI in small target vessels ≤2.75 mm RVD as well as in patients treated with stent sizes ≤3.0 mm diameter. These findings are in line with the recent results of the BIORESORT trial for the pre-specified subgroup analysis in small vessels up to 2.5 mm in diameter. At 36 months, the TLF rates were 7% (36/525) in subjects treated with BP-SES, 9.5% (46/496) in subjects treated DP-EES, and 10% (48/485) in subjects treated with a DP-ZES. Multivariate analysis showed that treatment with BP-SES in small coronary arteries was independently associated with statistically significantly lower TLR rates up to 3 years post procedure. It can be speculated that ultra-thin struts cause less arterial injury during intervention, which results in less inflammatory response and improved endothelialization leading to lower event rates. In addition, stent platforms with thinner struts may also be less thrombogenic compared to stent platforms with thicker struts because of less flow disturbance. To further investigate whether the positive treatment effect of BP-SES observed in the small vessel subgroup can be linked to the ultrathin struts of 60 μm, we repeated the regression analysis for patients treated with stents ≤3.0 mm in diameter corresponding to strut width of only 60 μm. Again, we observed a positive effect on both TLF and TV-MI rates in BP-SES subjects suggesting a positive effect on clinical outcomes by implantation of DES with ultra-thin struts. There are various design elements in all sizes of BP-SES, which are distinct from DP-EES: The antiproliferative drug (sirolimus vs. everolimus), the polymer (bioresorbable vs. durable), and the existence of an additional passive coating on the metallic backbone (amorphous silicon carbide vs. none). It has been speculated if one of these or their combination are advantageous when BP-SES are used. However, this did not translate in a measurable difference in clinical outcome when looking at the large meta-analysis of Cassese et al. However, there is one more relevant distinction of BP-SES which is its differentiated design of ultrathin struts of 60 μm only in stent diameters up to 3 mm compared to 81 μm in DP-EES. Hence, this special design feature appears to be the valid explanation for the benefit of BP-SES with use of stent diameters up to 3 mm, which is the novel finding of this IPD analysis.

5 | LIMITATIONS

First, this IPD was a retrospective analysis and included studies, which all differed in design. Even though we had tested for a study effect, the differences in baseline characteristics and design might have influenced our results (e.g., differences in adjudication of clinical events). Second, event rates after treatment with second and third generation DES are low. Effects of treatment with either BP-SES or DP-EES might have even been more pronounced in certain subgroups if more IPD would have been available. Third, RVD assessment was not based on corelab assessment only but also the investigators’ assessment in quite a large set of patients (BIOFLOW-III). Additionally, subjects were counted in the RVD ≤2.75 mm group (or stent size ≤3.0 mm diameter) if at least one target lesion RVD was ≤2.75 mm (or stent size ≤3.0 mm diameter); thus patients who underwent concomitant treatment of a target lesion with RVD > 2.75 mm (or stent size >3.0 mm diameter) were also counted in this group, which may have impacted the results. Last, even when the components of TLF were consistent over the four included trials, defined as a composite of CD, TV-MI, and clinically driven TLR, in BIOFLOW-V a modified version of the third universal MI definition was used for analysis of the primary endpoint. Because of a more sensitive MI definition more TV-MI were counted in BIOFLOW-V. However, when analyzing the BIOFLOW-V data using the third universal MI definition in a sensitivity analysis, numerically lower rates of TLF were observed as a result of lower rates of TV-MI at 12 months in both treatment groups, compared to the primary analysis. Overall the magnitude and direction of differences in TLF and TV-MI rates between BP-SES and DP-EES were similar between the primary analysis definition and the third Universal definition.

6 | CONCLUSION

Results of this IPD analysis suggest that BP-SES is an equally safe and more efficacious treatment option in patients suffering from coronary artery disease. Patients with small target vessels (RVD ≤2.75 mm) or treated with stents of sizes ≤3.0 mm in diameter may benefit most from treatment with BP-SES when compared to DP-EES.

ACKNOWLEDGMENTS

We thank Barbara Widmann, Stephanie Sauter, and Lidia Mukina for their expert medical writing assistance and support in statistical analysis.

CONFLICT OF INTEREST

Ralph Toelg declares receiving speakers honoraria from BIOTRONIK. Ton Slagboom declares having personal consultancy agreement with BIOTRONIK. Johannes Waltenberger reports personal fees and non-financial support from BIOTRONIK, and personal fees from Bayer, Boehringer Ingelheim and Daichi-Sankyo, Thierry Lefèvre reports proctoring for Edwards Lifescience, Abbott Vascular and Terumo, David E. Kandzari reports institutional research/grant support from BIOTRONIK, Boston Scientific, Medinol, Medtronic, and Orbus Neich, and personal consultancy honoraria from Boston Scientific, Cardiovascular Systems Inc., and Medtronic, Jacques Koolen reports lecturer and consultant fees from Medtronic, and proctoring for BIOTRONIK. Gert Richardt and Shigeru Saito have no conflict of interest to declare.
REFERENCES

1. Stefanini GG, Byrne RA, Windecker S, Kastrati A. State of the art: coronary artery stents - past, present and future. EuroIntervention. 2017;13:706-716.
2. Iglesias JF, Roffi M, Degraewe S, et al. Orsiro cobalt-chromium sirolimus-eluting stent: present and future perspectives. Expert Rev Med Devices. 2017;14:773-788.
3. Kalnins U, Erglis A, Dinne I, Kumsars I, Jegere S. Clinical outcomes of silicon carbide coated stents in patients with coronary artery disease. Med Sci Monit. 2002;8:i8-i12.
4. Windecker S, Haude M, Neumann FJ, et al. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial. Circ Cardiovasc Interv. 2015;8:e001441.
5. Kandzari DE, Mauri L, Koolen JJ, et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017;390:1843-1852.
6. Saito S, Tölg R, Witzenbichler B, et al. A randomized, intercontinental, multicenter study to assess the safety and effectiveness of the orsiro sirolimus eluting stent in the treatment of subjects with de novo coronary artery lesions BIOFLOW IV - primary outcome target vessel failure at 12 months. EuroIntervention. 2019;15:e1006–e1013.
7. Pilgrim T, Heg D, Roffi M, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet. 2014;384:2111-2122.
8. von Birgelen C, Kok MM, van der Heijden LC, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet. 2016;388:2607-2617.
9. Jensen LO, Thyssen P, Maeng M, et al. Randomized comparison of a biodegradable polymer ultrathin strut sirolimus-eluting stent with a biodegradable polymer biolimus-eluting stent in patients treated with percutaneous coronary intervention: the SORT OUT VII trial. Circ Cardiovasc Interv. 2016;9:e003610.
10. von Birgelen C, Zocca P, Buiten RA, et al. Thin composite wire strut, durable polymer-coated (resolute onyx) versus ultrathin cobalt-chromium strut, bioreabsorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. Lancet. 2018;392:1235–1245.
11. Yamaji K, Zanchin T, Zanchin C, et al. Unselected use of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for coronary revascularization. Circ Cardiovasc Interv. 2018;11:e006741.
12. Waltenberger J, Brachmann J, van der Heyden J, et al. Real-world experience with a novel biodegradable polymer sirolimus-eluting stent: twelve-month results of the BIOFLOW-III registry. EuroIntervention. 2015;11:1106–1110.
13. SCAAR. Restenosis first year in most used stents implanted >1000 times in Sweden, 2007 - January 23, 2018. https://www.ucr.uu.se/swedeheart/99-scaar/forskning-scaar. Accessed November 13, 2019.
14. Lipinski MJ, Forrestal BJ, Iantorno M, Torguson R, Waksman R. A comparison of the ultrathin orsiro hybrid sirolimus-eluting stent with contemporary drug-eluting stents: a meta-analysis of randomized controlled trials. Cardiovasc Revasc Med. 2018;19:5-11.
15. Zhu P, Zhou X, Zhang C, Li H, Zhang Z, Song Z. Safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer drug-eluting stents: a meta-analysis of randomized trials. BMC Cardiovasc Disord. 2018;18:170.
16. Bangalore S, Toklu B, Patel N, Feit F, Stone GW. Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease: a meta-analysis of randomized trials. Circulation. 2018;138:2216-2226.
17. Cassese S, Nidrepepa G, Byrne RA, et al. Outcomes of patients treated with ultrathin-strut biodegradable polymer sirolimus-eluting stents versus fluoropolymer-based everolimus-eluting stents: a meta-analysis of randomised trials. EuroIntervention. 2018;14:224-231.
18. Lefèvre T, Haude M, Neumann F-J, et al. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: 5-year outcomes of the randomized BIOFLOW-II trial. JACC Cardiovasc Interv. 2018;11:995-1002.
19. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351.
20. Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 2014;100:153-159.
21. Sioutis GC, Piccolo R, Praz F, et al. Percutaneous coronary interventions for the treatment of stenoses in small coronary arteries: a network meta-analysis. JACC Cardiovasc Interv. 2016;9:1324-1334.
22. Hermiller JB, Rutledge DR, Mao VW, et al. Clinical outcomes in real-world patients with small vessel disease treated with XIENCE V(r) everolimus-eluting stents: one year results from the XIENCE V(r) USA condition of approval post-market study. Catheter Cardiovasc Interv. 2014;84:7-16.
23. Saito S, Iwabuchi M, Muramatsu T, et al. PLATINUM Japan SV: platinum chromium everolimus-eluting stent in small vessels. Cardiovasc Revasc Med. 2012;13:147-148.
24. Saito S, Valdes-Chavarri M, Richardt G, et al. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (clinical evaluation of new terumo drug-eluting coronary stent system in the treatment of patients with coronary artery disease) trial. Eur Heart J. 2014;35:2021-2031.
25. Iglesias JF, Heg D, Roffi M, et al. Long-term effect of ultrathin-strut versus thin-strut drug-eluting stents in patients with small vessel coronary artery disease undergoing percutaneous coronary intervention: a subgroup analysis of the BIOSCIENCE randomized trial. Circ Cardiovasc Interv. 2019;12:e008024.
26. Teirstein PS, Meredith IT, Feldman RL, et al. Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions. Catheter Cardiovasc Interv. 2015;85:207-215.
27. Bartorelli AL, Serruys PW, Miquel-Hebert K, Yu S, Pierson W, Stone GW. An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials. Catheter Cardiovasc Interv. 2010;76:60-66.
28. Cannon LA, Kereiakes DJ, Mann T, et al. A prospective evaluation of the safety and efficacy of TAXUS element paclitaxel-eluting stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERUSE small vessel trial. EuroIntervention. 2011;6:920-927.
29. Wohle J, Markovic S, Rottbauer W, et al. Bioreabsorbable polymer sirolimus-eluting coronary stent compared with permanent polymer everolimus-eluting coronary stent implantation for treatment of small vessel coronary artery disease: CENTURY II trial. EuroIntervention. 2016;12:e167-e174.
30. Buiten RA, Ploumen EH, Zocca P, et al. Outcomes in patients treated with thin-strut, very thin-strut, or ultrathin-strut drug-eluting stents in small coronary vessels: a prespecified analysis of the randomized BIO-RESORT trial. JAMA Cardiol. 2019;4:659-669.
31. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400-1409.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.